Reply to: “Assessment of hepatic fibrosis in MAFLD: a new player in the evaluation of residual cardiovascular risk?”
By: Zelber-Sagi S., Schonmann Y., Yeshua H., Bentov I.
Published in: Digestive and Liver Disease
SDGs : SDG 03 | Units: Social Welfare & Health Sciences | Time: 2021 | Link
Description: